FDA Classifies Multiplex Test for New Respiratory Bugs as Class II
Published Date: 8/21/2025
Rule
Summary
The FDA is officially classifying a new multiplex respiratory panel as a Class II device, meaning it has special safety rules to follow. This device helps doctors quickly spot both common and new respiratory germs in patient samples. This change makes it safer and easier for patients to get access to these helpful tests without extra delays or costs.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
New Class II Respiratory Test
The FDA is classifying a new multiplex respiratory panel as Class II, which means it must follow special safety controls. The test helps doctors quickly detect and identify both emerging and common respiratory pathogens in human clinical specimens, and the FDA says this classification will provide reasonable assurance of safety and will enhance patients' access by reducing regulatory burdens.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in